Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
New Worlds - New Solutions. Research and innovation as basis for developing Europe in a global context. (CHC09)

Framework: FP7 — Capacities
Programme: Support for the coherent development of research policies
Destination: Women innovators
Action type: Coordination and support actions
Countries involved: Sweden
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2008-12-03
End date: 2009-12-02
Duration (months): 12.0
Total project cost (EUR): 720400.0
EU funding (EUR): 200000.0
Participants: 1
Project status: CLOSED

The conference will lay the ground for considerations about future directions for research, development and innovation in Europe as seen from a broad societal user perspective. The current framework programme for Research and Technological Development (FP7) ends in 2013. Now is the time to start a process on how to set priorities for future research activities. This discussion takes place in a situation where Europe and the rest of the world are facing quickly arising global system changes. The question is how we should respond to and take control of environmental, business, social and other challenges or shocks. The purpose of the conference is to discuss these challenges and to initiate the formulation of policies intended to strengthen Europe´s position in the world. Emerging consequences of global transformation - often perceived as problems - ought to be turned into opportunities to increase quality of life. Here European research, development and innovation have a key role to play.

Keywords: research,research policy,europe in a global context
CARDIO REPAIR EUROPEAN MULTIDISCIPLINARY INITIATIVE (CARE-MI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Spain,Portugal,Spain,United Kingdom,Germany,Netherlands,France,Belgium,Slovenia,Belgium,Netherlands,Netherlands,Israel,Spain,Spain
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2015-09-30
Duration (months): 66.0
Total project cost (EUR): 14939184.49
EU funding (EUR): 11305102.8
Participants: 20
Project status: CLOSED

Ischemic Heart Disease (IHD) is the biggest single cause of death in Europe and in the developed world. Angioplasty and stents are successful in re-establishing perfusion of ischemic myocardium and have helped to reduce early mortality after acute myocardial infarction (AMI). However damaged tissue is not recovered and, therefore, this is always followed by cardiac remodelling and Chronic Heart Failure (CHF). CHF is a terminal disease with an annual mortality rate of ~18% with no cure besides heart transplantation, only available to a minority of patients. Autologous cell therapy has been proposed as a solution and clinically tested but has proven marginally effective at best. Its cost and the complexity of clinical procedures make it unsuitable for treating the large number of patients that need affordable and readily available products to treat the acute phase of the disease. Moreover, most of these approaches are predicated on the outmoded concept that the adult human myocardium lacks regenerative capacity. Recent findings show that adult myocardium harbours a population of resident pluripotent cells with the characteristics of true cardiac stem cells (CSC) able to regenerate contractile myocardium. This opens novel therapeutic avenues capable of producing real anatomical and functional regeneration. The CARE-MI proposal addresses the clinical implementation of this recent paradigmatic change. We will clinically test and further develop myocardial regenerative therapies based on the in situ activation, multiplication and differentiation of the endogenous CSCs with the aim to provide therapies that are: a)Affordable, in terms of the production costs of the medicinal product b)Readily and widely available, implying that the product may be easily stored and readied for application at all times at minimum cost. c)Easy to apply and compatible with current clinical standard of care for AMI, including the widespread use of PTCA interventions

Keywords: cardiac stem cells (csc),ischemic heart disease,in-patient trials,allogeneic transplant,growth factors
Zebrafish Regulomics for Human Health (ZF-HEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,France,United Kingdom,Netherlands,Netherlands,Germany,Germany,United Kingdom,Italy,Germany,Switzerland,United Kingdom,Australia,Norway,Spain
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-07-01
End date: 2015-12-31
Duration (months): 66.0
Total project cost (EUR): 15313507.22
EU funding (EUR): 11375000.0
Participants: 20
Project status: CLOSED

In recent years, the zebrafish has emerged as a new vertebrate model organism for biomedical research which offers a unique combination of traits: a short generation time, small size and efficient breeding procedures make it the best choice among vertebrates for forward genetic screening and small-molecule screens, including toxicology, while the transparent embryo and larva offers unique opportunities for imaging of cell movement and gene expression in a developing organism. Building on recent advances in the zebrafish field, we will conduct high-throughput phenotyping of at least a thousand regulatory genes relevant for common human diseases, by behavioural assays (for viable mutants), 3D / 4D imaging and expression profiling (including high-throughput sequencing). We will include mutants generated by TILLING and by the new zinc finger nuclease method, as well as mutants from earlier forward-genetics screens. A phenotyping effort of this scale has never been undertaken before in any vertebrate organism. Complementing the study of mutants relevant for neurological disorders, we will produce an atlas of gene expression in the brain, the most comprehensive one in a vertebrate. We will further perform a genome-wide characterisation of regulatory elements of potential disease genes by a combination of bioinformatics and transgenics. Small-molecule screening for mutant rescue or disease-relevant processes will identify candidate drugs and provide insights into gene function. Our increasing knowledge on the regulators and their interactions with regulatory targets will be integrated with knowledge at cellular and organismic level. By capitalising on the virtues of the zebrafish system, this systems biology approach to the regulome will gain unique knowledge complementing ongoing work in mammalian systems, and provide important new stimuli for biomedical research.

Keywords: model organism,phenotyping,disease genes,bioinformatics,genetic variation,drug screening
EUropean Cross Border Care Collaborations Short Title: CrossEurope (EUCBCC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Switzerland,Belgium,Netherlands,Germany,Spain,Slovenia,Estonia,Finland,Hungary,Italy,Austria
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2013-10-31
Duration (months): 42.0
Total project cost (EUR): 5766893.0
EU funding (EUR): 4499437.0
Participants: 14
Project status: CLOSED

EUCBCC aims to facilitate a process whereby Europe's citizens can make informed choices about whether to seek health care in another Member State and, if they so choose, to ensure that the admin and clinical processes are straightforward and ensure continuity of care. It takes as its starting point the recent draft Directive on Patients' Rights, augmented by the existing body of research on cross-border care. It then focuses on those areas where the necessary information is incomplete and seeks to fill the gaps. It is equally important to state what it does not do. It does not seek to quantify the scale of movement because our earlier research reveals this to be a dynamic area where data are often unavailable and rapidly become out of date. EUCBCC firstly examines five aspects of health care delivery where it will be necessary for procedures to be compatible if patients are to be assured that the care they receive is safe, of adequate quality, and capable of providing continuity where some parts of the overall care process are provided in different Member States. These are: provisions with regard to the continuing quality health professionals; treatment pathways; public reporting of quality; content and scope of medical records; and medical prescribing. Secondly, it looks at three areas where there is already cross-border collaboration, to identify practical issues that have arisen and how they have (not) addressed. These areas of practice are collaborations between hospitals in border areas, telemedicine, and dentistry. The research on the first set of topics generally takes place on two levels. The first involves a series of pan-European surveys to identify the nature of the phenomenon in, as far as possible, all Member States. The second involves focused studies in key areas geographical of subject areas that capture important issues. The methods used are both quantitative and qualitative and involve contributions from a broad range of disciplines.

Keywords: cross border collaboration,health,impact,hospital joint investment,cross border care,telemedicine,ehealth,electronic patient record,prescriptions,quality of care,patient choice
Security UPgrade for PORTs (SUPPORT)

Framework: FP7 — Cooperation
Programme: Security
Destination: Intelligent surveillance and enhancing border security
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Finland,Norway,United Kingdom,Sweden,Cyprus,Austria,Latvia,France,Greece,Netherlands,United Kingdom,Ireland,Spain,Netherlands,Portugal,Ireland
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-07-01
End date: 2014-06-30
Duration (months): 48.0
Total project cost (EUR): 14622990.91
EU funding (EUR): 9920607.0
Participants: 22
Project status: CLOSED

Port security remains of paramount importance for Europe both due to potential threats on passenger life and the potential for crippling economic damage arising from intentional unlawful attacks on port facilities. Challenges arise due to the complexity of operational modalities of sea and hinterland traffic and the lack of efficient organisational and technological interfaces linking ports to border control authorities, the police and other intervention forces, and transport-logistics operators. Considerable progress with port security has been achieved in recent years primarily associated with adoption of the International Ship and Port Facility Security (ISPS) Code . SUPPORT is aimed at building on these achievements by engaging representative stakeholders to guide the development of next generation solutions for upgraded preventive and remedial security capabilities in European ports. The overall benefit will be the secure and efficient operation of European ports enabling uninterrupted flows of cargo and passengers while suppressing illegal immigration and trafficking of drugs, weapons and illicit substances all in line with the efforts of FRONTEX and EU member states. SUPPORT will deliver public formal specifications and open standards based tools that will aid security upgrade in EU ports and will be complementary to and usable by other EU projects and initiatives in this area. Emphasis will be given to bring together advances from research on security with results from the main EU projects in maritime and intermodal transport, specifically those concerned with security and interoperability issues. Thus, SUPPORT will address ‘total’ port security upgrade solutions encompassing legal, organisational, technology and human factors perspectives. These solutions should provide substantial improvements in the performance, reliability, speed and cost of European port security which will be demonstrated during the course of the project.

Keywords: port security
Enhanced Protective Immunity Against Filariasis (E PIAF)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Cameroon,Ghana,United Kingdom,Germany,Germany,France,United Kingdom,Togo,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2014-08-31
Duration (months): 54.0
Total project cost (EUR): 6634715.4
EU funding (EUR): 5000000.0
Participants: 11
Project status: CLOSED

Filarial infections remain a major public health problem in West and Central Africa. Three filarial species are involved: Onchocerca volvulus (onchocerciasis or river blindness); Wuchereria bancrofti (lymphatic filariasis); and Loa loa (the eye worm). Treatment of onchocerciasis with ivermectin has been successful in many situations but emergence of drug resistance and risk of severe adverse reactions associated with L loa co-infections is restricting the implementation of mass treatment and consequently alternate approaches to control are required. Studies with animal models have identified the general mechanisms of protective immunity while human studies have drawn attention to immune regulatory processes that influence clinical presentations Together, these observation provide a basis for vaccine development. The next challenge is to identify target antigens and ensure appropriate formulation and delivery to promote protective responses and avoid any pathology. This project aims to: 1, use transciptomics and bioinformatics to identify the parasite molecules that are targets of protective immunity and that may influence the regulation of such responses; and 2, microarray technologies and bioinformatics to determine the pathways that lead to expression of protective immunity. Cohorts of onchocerciasis patients who have received treatment with ivermectin or tetracycline, or are co infected with either W bancrofti or L loa provide both input to the pathway studies and a means of validation of the computer assimilations. Confirmation of the mechanisms and targets of protective immunity and validation of computer assimilations will also be investigated using the O ochengi-cattle model that also enables experimentation under natural challenge. Litomosoides sigmodontis in mice provides a robust and rapid validation of results obtained from computation relating to expression and regulation of protective responses and a primary system for screening vaccine candidates

Keywords: filariasis,onchocerciasis,vaccines,immunity,functional genomics,bioinformatics,pathway biology,co-infections,animal models
RICHE – a platform and inventory for child health research in Europe (RICHE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Ireland,Italy,Netherlands,Norway,United Kingdom,Slovenia,Austria,Poland,Iceland,Finland,Czechia,United Kingdom,Germany,United Kingdom,Romania,Netherlands,Estonia,Portugal,United Kingdom,Hungary,Sweden
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2013-07-31
Duration (months): 42.0
Total project cost (EUR): 1778939.66
EU funding (EUR): 1499307.0
Participants: 26
Project status: CLOSED

The European Commission and other funding agencies make a large investment in child health research. The health of our children is satisfactory, but there are serious concerns, for example, obesity, mental health, alcohol abuse, and sexuality. We know that there are strong links between the health of young people and their social inclusion and level of education. Our objective is to establish a sustainable network for researchers, funders, policy makers, advocates and young people in Europe, to support collaboration in developing the future of child health research. We will produce an inventory of research, and reports, on gaps in research, and on roadmaps for the future of research. Our co-ordination will establish a unique, open, multi-lingual platform for child health research. This will embrace the full multi-disciplinary diversity of European research, while addressing fragmentation by making the parts visible, and supporting multi-lingual input and searching. We will develop formal processes for finding gaps in research, and for making roadmaps. We will use these to find current gaps, and make roadmaps for the future, including for the necessary research capacity. We will promote our work and our results in a series of meetings open to researchers and other stakeholders. Our consortium is a multi-disciplinary team, with great experience in doing innovative child health research in Europe, in developing, and in delivering child health strategies at national, and European level. This mixture of skills and experience gives us a unique perspective on the strategic problems at European level. We have an Expert Group, including young people, advocates, and researchers who will support us. RICHE will support the development and implementation of child health research strategies, and the use of evidence for child health action. These in turn will support innovative research, improve social policy for children, and so improve the quality of life of European children.

Keywords: child health inventory taxonomy virtual community multilingual platform research roadmap lifecourse
Vitamin D And LIfestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention (DALI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Spain,United Kingdom,Austria,Finland,Belgium,Denmark,Poland,Italy,Ireland,Netherlands,United Kingdom,Denmark,Switzerland,Spain
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2015-12-31
Duration (months): 70.0
Total project cost (EUR): 3849476.54
EU funding (EUR): 2999429.0
Participants: 16
Project status: CLOSED

Europe is facing a rapidly growing threat from Type 2 diabetes mellitus (T2D), which is undoubtedly associated with an unhealthy diet and a more sedentary lifestyle. Evidence is accumulating that gestational diabetes mellitus (GDM) may be playing a role in this process. Thus it provides a significant opportunity for preventing future T2D. Not only is GDM prevalence on the rise, but intrauterine exposure to hyperglycaemia predisposes the offspring to diabetes and obesity. Another putative contributing factor is a low vitamin D status, which is also increasing in prevalence and may have causal links with both obesity and decreased glucose tolerance. The main aims of this project are: 1) to establish the current status of the prevalence of GDM in Europe and facilitate the adoption of a single diagnostic approach and 2) to deliver the best strategy that prevents GDM. The latter was deemed as not fully feasible within the scope of this call and our decision was to test the most relevant approaches (diet, exercise, vitamin D, alone or in combination) against surrogate variables of GDM (fasting blood glucose, insulin sensitivity, pregnancy weight gain) to come up with the best intervention for entry into a definitive GDM prevention trial. Deliverables include the sample size and modus operandi for such a trial. Value will be added to the project by 1) Assessing variables modifying the uptake of preventive interventions, 2) Exploring health costs of GDM and potential savings of preventive approaches, 3) Improving pathophysiological understanding by assessing intervention effect on several parameters in mother and foetus and 4) Facilitating future research through a well defined cohort of mother-offspring pairs and comprehensive biobanking.

Keywords: gestational diabetes mellitus,life style intervention,behavioural science,vitamin d,health costs,biobanking,database
Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy. (FIGHT-MG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Greece,Israel,Italy,Norway,Switzerland,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-12-01
End date: 2014-05-31
Duration (months): 54.0
Total project cost (EUR): 7767250.66
EU funding (EUR): 5917421.0
Participants: 12
Project status: CLOSED

Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies. We will address the: 1. Natural course of disease: determine factors associated with disease onset and/or affecting the course of disease and patients&apos; quality of life in subgroups of MG patients including children, twins, females and elderly patients. 2. Etiology of MG: identify new genetic, epigenetic and environmental risk factors and investigate immunological key molecules associated with MG onset. 3. Pathogenic mechanisms at the NMJ: a) study molecular changes in the NMJ by proteomic, genetic, epigenetic and microRNA analyses in MG patients and experimental models; b) analyze morphological changes at the NMJ in mouse models expressing YFP nerves and mice transgenic for mini-agrin; c) evaluate the capacity of muscle cell satellites from MG patients to regenerate muscle and form new endplates in immunodeficient mice. 4. New diagnostic and monitoring assays: a) identify pathogenic and protective factors in MG sera; b) improve the sensitivity of current assays; c) Identify new biomarkers associated with different MG subgroups by proteomic and microRNA analyses; d) Identify patients&apos; response to treatment and liability to side effects by pharmacogenomic analyses. 5. Novel therapies: a) study new cell-based therapies aimed at regulating the autoimmune response by regulatory T cells or mesenchymal stem cells in humanized mice; b) immunoadsorb pathogenic antibodies; c) test non-cell based immmunomodulatory therapies; d) target epigenetic regulators. This multidisciplinary project linking basic researchers with clinical neurologists, SMEs and several European patient associations should favor a translational approach for improved MG management

Keywords: myasthenia,neurological disorder,autoimmune,neuromuscular junction,acetylcholine receptor,antibodies,inflammation,thymus,treg cells,musk,epigenetic,mirna,databas,biobank
Accessing Medicines in Africa and South Asia (AMASA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Switzerland,Uganda,South Africa,United Kingdom,India
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2013-10-31
Duration (months): 42.0
Total project cost (EUR): 3888729.37
EU funding (EUR): 2995790.0
Participants: 8
Project status: CLOSED

The main aim of the proposed research is to investigate how the interplay of patent regimes, pharmaceutical regulation, availability of drug production facilities, health care infrastructure and service provision, and engagement by foreign donors influence appropriate, affordable access to medicines in South Asia and Sub-Saharan Africa. We aim to map patterns of production, distribution, supply and consumption of medicines within seven health care areas – HIV/AIDS, Malaria, Reproductive Health, Tuberculosis (TB) control, Mental Health, Pain Management and Diabetes. We also plan to investigate the strategies and influence of selected Indian producers who are active as exporters, partners in joint ventures, or as direct producers in the selected South Asian and African countries.

Keywords: access to medicines,global commodity chains